Advertisement

Advantages and Limitations

  • Shaista HafeezEmail author
  • Robert Huddart
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

CT alone has conventionally informed radiotherapy planning. It provides anatomical information for delineation and electron density for dose calculation. Integrating PET-CT for radiotherapy planning offers the opportunity to individualize treatment and improve patient outcome. PET-CT’s molecular insight of tumour biology could facilitate a move away from ‘one-size-fits-all’ prescription to more accurate personalized radiotherapy [1].

Keywords

Dose Calculation Radiotherapy Planning Dose Painting Biological Target Volume Precise Registration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We acknowledge NHS funding to the NIHR Biomedical Research Centre for Cancer and to Cancer Research UK (CRUK).

Conflict of Interest Notification

No conflicts of interest.

References

  1. 1.
    Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007;48(6):18N–21N.PubMedGoogle Scholar
  2. 2.
    De Ruysscher D, Kirsch CM. PET scans in radiotherapy planning of lung cancer. Radiother Oncol. 2010;96(3):335–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiti A, Kirienko M, Gregoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol. 2010;96(3):277–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56(19):4509–15.PubMedGoogle Scholar
  5. 5.
    Thorwarth D, Geets X, Paiusco M. Physical radiotherapy treatment planning based on functional PET-CT data. Radiother Oncol. 2010;96(3):317–24.Google Scholar
  6. 6.
    Coffey M, Vaandering A. Patient setup for PET-CT acquisition in radiotherapy planning. Radiother Oncol. 2010;96(3):298–301.Google Scholar
  7. 7.
    Scripes PG, Yaparpalvi R. Technical aspects of positron emission tomography/computed tomography in radiotherapy treatment planning. Semin Nucl Med. 2012;42(5):283–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Bettinardi V, Picchio M, Di Muzio N, Gianolli L, Gilardi MC, Messa C. Detection and compensation of organ/lesion motion using 4D-PET-CT respiratory gated acquisition techniques. Radiother Oncol. 2010;96(3):311–6.Google Scholar
  9. 9.
    Weber WA. Quantitative analysis of PET studies. Radiother Oncol. 2010;96(3):308–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Nestle U, Schaefer-Schuler A, Kremp S, Groeschel A, Hellwig D, Rube C, Kirsch CM. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34(4):453–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.The Royal Marsden NHS Foundation TrustSuttonUK
  2. 2.The Institute of Cancer ResearchLondonUK

Personalised recommendations